Article

Breast Cancer Treatment Linked to Functional Decline in Older Women

Older women undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically.

Older women undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically, according to a new study in the Journal of the American Geriatrics Society.

The effect of chemotherapy on functional status can be critical for older adults, as declining function can inhibit the ability to live independently and perform daily activities. Additionally, previous studies have shown that older individuals with breast cancer who demonstrated a decline in physical function in the first 2 years after diagnosis had poorer 10-year survival.

For the study, the researchers aimed to detect common changes in patients’ ability to perform daily activities after receiving chemotherapy and to pinpoint why some women recovered their ability to function normally and others did not.

Click to continue reading on Specialty Pharmacy Times.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com